Lonafarnib

Brand names: Zokinvy · Active ingredient: Lonafarnib

In short: ZOKINVY is indicated in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above: To reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS) For the treatment of processing-deficient Progeroid Laminopathies with either: Heterozygous LMNA mutation wi

Forms & strengthsCapsules: 50 mg, opaque yellow with “LNF” and “50” printed in black 75 mg, opaque light orange with “LNF” and “75” printed in black
LabelSentynl Therapeutics, Inc.
Label updatedJan 16, 2026

What is Lonafarnib used for?

ZOKINVY is indicated in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above:

To reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS)

For the treatment of processing-deficient Progeroid Laminopathies with either:

Heterozygous LMNA mutation with progerin-like protein accumulation

Homozygous or compound heterozygous ZMPSTE24 mutations

Limitations of Use

ZOKINVY is not indicated for other Progeroid Syndromes or processing-proficient Progeroid Laminopathies. Based upon its mechanism of action, ZOKINVY would not be expected to be effective in these populations.

Lonafarnib dosage

The starting dosage of ZOKINVY for patients with a BSA of 0.39 m2 and above is 115 mg/m2 twice daily with morning and evening meals to reduce the risk of gastrointestinal adverse reactions . An appropriate dosage strength of ZOKINVY is not available for patients with a BSA of less than 0.39 m2

.

After 4 months of treatment, increase the dosage to 150 mg/m2 twice daily with morning and evening meals .

Round all total daily dosages to the nearest 25 mg increment .

If a dose is missed, take the dose as soon as possible with food, up to 8 hours prior to the next scheduled dose. If less than 8 hours remain before the next scheduled dose, skip the missed dose, and resume taking ZOKINVY at the next scheduled dose.

Table 1 provides the BSA-based dosage recommendations for the starting dosage of 115 mg/m2 twice daily.

BSA (m

2

) | Total Daily Dosage Rounded to Nearest 25 mg | Morning Dosing

Number of Capsule(s) | Evening Dosing

Number of Capsule(s)

ZOKINVY 50 mg | ZOKINVY 75 mg | ZOKINVY 50 mg | ZOKINVY 75 mg

0.39 - 0.48 | 100 | 1 | 1

0.49 - 0.59 | 125 | 1 | 1

0.6 - 0.7 | 150 | 1 | 1

0.71 - 0.81 | 175 | 2 | 1

0.82 - 0.92 | 200 | 2 | 2

0.93 – 1 | 225 | 1 | 1 | 2

Table 2 provides the BSA-based dosage recommendations for the dosage of 150 mg/m2 twice daily.

BSA (m

2

) | Total Daily Dosage Rounded to Nearest 25 mg | Morning Dosing

Number of Capsule(s) | Evening Dosing

Number of Capsule(s)

ZOKINVY 50 mg | ZOKINVY 75 mg | ZOKINVY 50 mg | ZOKINVY 75 mg

0.39 - 0.45 | 125 | 1 | 1

0.46 - 0.54 | 150 | 1 | 1

0.55 - 0.62 | 175 | 2 | 1

0.63 - 0.7 | 200 | 2 | 2

0.71 - 0.79 | 225 | 1 | 1 | 2

0.8 - 0.87 | 250 | 1 | 1 | 1 | 1

0.88 - 0.95 | 275 | 2 | 1 | 1

0.96 – 1 | 300 | 2 | 2

Adverse Reaction | Severity | Monitoring and Dose Modifications for ZOKINVY

QTc Interval Prolongation

| If the QTc interval is greater than or equal to 500 msec | Withhold ZOKINVY until QTc interval is less than 470 msec, then resume ZOKINVY at same dosage.Monitor electrocardiograms (ECGs) prior to initiating ZOKINVY, during treatment, and as clinically indicated.

Gastrointestinal Adverse Reactions

| For patients who have increased their dose of ZOKINVY to 150 mg/m2 twice daily and are experiencing repeated episodes of vomiting and/or diarrhea resulting in dehydration or weight loss | The dose of ZOKINVY can be reduced to the starting dose of 115 mg/m2 twice daily .Ensure ZOKINVY is taken with the morning and evening meals and with an adequate amount of water.

CYP3A Drug Interactions

| When moderate CYP3A inhibitors are added for a patient already on steady state ZOKINVY | No dosage adjustment for ZOKINVY is recommended. …

How to take Lonafarnib — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Dosing

Advise patients and caregivers that ZOKINVY should be taken twice daily with the morning and evening meals.

Inform patients and caregivers that if a dose is missed, the next dose should be given as soon as possible up to 8 hours prior to the next scheduled dose. If less than 8 hours remain before the next scheduled dose, the patient should skip the missed dose and resume taking ZOKINVY at the next scheduled dose.

Preparation and Administration

Advise patients to swallow the capsule whole with water. The capsules should not be chewed.

For patients unable to swallow capsules, advise patients and caregivers that the contents of ZOKINVY can be mixed with Ora Blend SF or Ora-Plus. For patients unable to access or tolerate Ora Blend SF or Ora-Plus, the contents of ZOKINVY can be mixed with orange juice or applesauce. Advise patients not to mix the contents of ZOKINVY with juice containing grapefruit or Seville oranges. Advise patients and caregivers that the mixture must be prepared fresh for each dose and taken within approximately 10 minutes of mixing. …

Warnings & precautions

Do not take this medicine if: ZOKINVY is contraindicated in patients taking:

Strong CYP3A inhibitors

Strong or moderate CYP3A inducers

Midazolam

Lovastatin, simvastatin, or atorvastatin

ZOKINVY prolongs the QTc interval. Prolongation of the QTc interval increases the risk of Torsade de pointes, other serious arrhythmias, and sudden death.

Avoid use of ZOKINVY in patients with a history of cardiac arrhythmias, as well as in other circumstances that may increase the risk of the occurrence of Torsade de pointes or sudden death, including symptomatic bradycardia, hypokalemia, or hypomagnesemia. Avoid use of ZOKINVY in combination with other drugs known or suspected to prolong the QTc interval .

Monitor ECGs prior to initiating ZOKINVY, during treatment, and as clinically indicated. If QTc interval is greater than 500 msec, withhold ZOKINVY until QTc interval is less than 470 msec, then resume ZOKINVY at same dosage.

Obtain serum electrolytes prior to initiating ZOKIVNY and during treatment as clinically indicated. Correct serum electrolyte abnormalities.

Coadministration of ZOKINVY with other drugs may result in clinically significant drug interactions . These drug interactions can lead to:

Reduced efficacy of ZOKINVY

Increased risk of adverse reactions from ZOKINVY or co-administered drugs

See Table 5 and Table 6 for steps to prevent or manage these clinically significant drug interactions, including dosage recommendations . Consider the potential for drug interactions prior to and during ZOKINVY therapy; review concomitant medications during ZOKINVY therapy; and monitor for adverse reactions.

Some patients treated with ZOKINVY developed laboratory abnormalities . …

Lonafarnib side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

A total of 84 subjects were treated with at least one dose of ZOKINVY with or without additional therapy, of which 8 were treated at a dosage of at least 115 mg/m2 twice daily for greater than or equal to 10 years.

The safety profile of ZOKINVY is based on 128 patient-years of treatment exposure (62 patients with HGPS and 1 patient with processing-deficient Progeroid Laminopathy with LMNA heterozygous mutation) and pooled results from two Phase 2 open-label, single-arm trials (n=63: 28 patients from Study 1 and 35 treatment naïve patients from Study 2). In Study 1, ZOKINVY treatment was initiated at 115 mg/m2 twice daily and increased to 150 mg/m2 twice daily after approximately 4 months for a total treatment duration of 24 to 30 months. Treatment naïve patients in Study 2 received ZOKINVY 150 mg/m2 twice daily for up to 36 months. In both studies, ZOKINVY was administered orally via capsules or the capsule contents were mixed with Ora Blend SF or Ora-Plus and administered orally as a suspension.

In these two studies, a total of 63 patients received ZOKINVY for a median duration of 2.2 years, with approximately 1.9 years at the recommended dose of 150 mg/m2 twice daily. …

Drug interactions

Table 5 presents clinically significant drug interactions involving drugs that affect ZOKINVY.

CYP3A Inhibitors

Clinical Impact | Lonafarnib is metabolized by CYP3A. Concomitant use of ZOKINVY with a strong CYP3A inhibitor may increase lonafarnib area under curve (AUC) and maximum concentration (Cmax)

, which may increase the incidence and severity of adverse reactions, including QTc interval prolongation. Prolongation of the QTc interval increases the risk of Torsade de pointes, other serious arrhythmias, and sudden death .

Prevention or Management | Strong CYP3A inhibitors | Use of ZOKINVY with strong CYP3A inhibitors is contraindicated . Avoid consumption of grapefruit or Seville oranges.

Moderate CYP3A inhibitors | No dosage adjustment for ZOKINVY is recommended when moderate CYP3A inhibitors are added to steady-state ZOKINVY . When initiating ZOKINVY in a patient who is currently on a moderate CYP3A inhibitor, the patient may be at increased risk of adverse reactions .

CYP3A Inducers

Clinical Impact | Coadministration of ZOKINVY with a strong CYP3A inducer decreases lonafarnib Cmax and AUC , which may reduce ZOKINVY efficacy.

Prevention or Management | Strong or moderate CYP3A inducers | Use of ZOKINVY with strong or moderate CYP3A inducers is contraindicated . …

About this medicine

ZOKINVY (lonafarnib) is a farnesyltransferase inhibitor. The chemical name for lonafarnib is 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H- benzo[1,2] cyclohepta [2,4-b]pyridin-11-yl]piperidin-1-yl]-2- oxoethyl]piperidine-1-carboxamide. Its molecular formula is C27H31Br2ClN4O2, molecular mass is 638.8 g/mol, and its chemical structure is depicted below.

ZOKINVY (lonafarnib) capsules for oral administration contain 50 mg or 75 mg of lonafarnib as the active ingredient and the following inactive ingredients: croscarmellose sodium, magnesium stearate, poloxamer 188, povidone, and silicon dioxide. The capsule shells of both strengths contain gelatin, titanium dioxide, and yellow iron oxide; the 75 mg capsule also contains red iron oxide. The imprinting ink contains ammonia solution, black iron oxide, butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, and shellac. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 97391d0c-943e-4c5a-8423-68e163aa7f50. Read the full official label on DailyMed.